相关实验视频

Updated: Jun 25, 2025

Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA

Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA

Published on: November 1, 2024

用AAV介导的基因疗法来治疗化剂

Diantha van de Vlekkert¹, Huimin Hu¹, Jason A Weesner¹

¹Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Molecular therapy : the journal of the American Society of Gene Therapy

|May 26, 2024

概括

使用AAV载体的基因疗法通过恢复NEU1酶活性,成功地治疗了小鼠的脂症 (粘脂症I). 这种方法为这种罕见的遗传疾病提供了有前途的治疗策略.

科学领域:

生物化学生物化学
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

脂症 (粘脂症I) 是一种罕见的遗传疾病,由NEU1酶缺乏引起,导致化分子的有毒积累.
临床表现包括全身和神经症状,目前没有可用的治疗选择.
Neu1的淘汰赛小鼠模型严重的化症,表现出广泛的细胞病理和器官功能障碍.

研究的目的:

为了评估腺相关病毒 (AAV) 介导的基因疗法的治疗疗效.
在小鼠模型中研究通过AAV矢量传递NEU1及其伴侣PPCA的潜力.

主要方法:

Neu1 淘汰赛小鼠接受了编码人类 NEU1 和 PPCA 的 scAAV2/8 载体的同时注射.
在接受治疗的小鼠身上进行了表型,生化和细胞分析,并与野生类型对照进行了比较.

主要成果:

AAV基因疗法恢复了NEU1在多个器官中的活性,包括大脑,心脏和肌肉.
接受治疗的小鼠显示了 lysosomal 储存的正常化,减少了 sialyl-oligosacchariduria 和减少了神经炎症.
恢复的NEU1功能导致疾病表型的逆转,治疗的小鼠在表型上与野生类型对照无法区分.

结论:

以AAV为媒介的基因疗法是一种可行的和有效的治疗策略,用于sialidosis.
这种方法有可能用于治疗与NEU1缺乏相关的其他溶酶体储存疾病.

关键词:

通过AAV介导的基因治疗.在CNS中,CNS是CNS.欧盟国家1 这就是PPCA.lysosomal 储存疾病 lysosomal 储存疾病这是一种化剂 (sialidosis).

更多相关视频

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Published on: October 18, 2022

Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification

Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification

Published on: October 11, 2024

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...